• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Five forces summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Therapy o Market segments o Comparison by Therapy o Chemotherapy - Market size and forecast 2019-2024 o Brachytherapy - Market size and forecast 2019-2024 o Ablation therapy - Market size and forecast 2019-2024 o Market opportunity by Therapy • Customer landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o APAC - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography o Market drivers o Market challenges o Market trends • Vendor Landscape o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o AbbVie Inc. o Amgen Inc. o AstraZeneca Plc o Bayer AG o Bristol-Myers Squibb Co. o Eli Lilly and Co. o F. Hoffmann-La Roche Ltd. o Gilead Sciences Inc. o Johnson & Johnson o Pfizer Inc. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibit • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2019 - 2024 ($ million) • 13: Global market: Year-over-year growth 2019 - 2024 (%) • 14: Five forces analysis 2019 & 2024 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2019 • 21: Other1 - Market share 2019-2024 (%) • 22: Comparison by Other1 • 23: Chemotherapy - Market size and forecast 2019-2024 ($ million) • 24: Chemotherapy - Year-over-year growth 2019-2024 (%) • 25: Brachytherapy - Market size and forecast 2019-2024 ($ million) • 26: Brachytherapy - Year-over-year growth 2019-2024 (%) • 27: Ablation therapy - Market size and forecast 2019-2024 ($ million) • 28: Ablation therapy - Year-over-year growth 2019-2024 (%) • 29: Market opportunity by Other1 • 30: Customer landscape • 31: Market share by geography 2019-2024 (%) • 32: Geographic comparison • 33: North America - Market size and forecast 2019-2024 ($ million) • 34: North America - Year-over-year growth 2019-2024 (%) • 35: Europe - Market size and forecast 2019-2024 ($ million) • 36: Europe - Year-over-year growth 2019-2024 (%) • 37: APAC - Market size and forecast 2019-2024 ($ million) • 38: APAC - Year-over-year growth 2019-2024 (%) • 39: ROW - Market size and forecast 2019-2024 ($ million) • 40: ROW - Year-over-year growth 2019-2024 (%) • 41: Key leading countries • 42: Market opportunity by geography ($ million) • 43: Impact of drivers and challenges • 44: Vendor landscape • 45: Landscape disruption • 46: Industry risks • 47: Vendors covered • 48: Market positioning of vendors • 49: AbbVie Inc. - Overview • 50: AbbVie Inc. - Business segments • 51: AbbVie Inc. - Key offerings • 52: AbbVie Inc. - Key customers • 53: AbbVie Inc. - Segment focus • 54: Amgen Inc. - Overview • 55: Amgen Inc. - Business segments • 56: Amgen Inc. - Key offerings • 57: Amgen Inc. - Key customers • 58: Amgen Inc. - Segment focus • 59: AstraZeneca Plc - Overview • 60: AstraZeneca Plc - Product and service • 61: AstraZeneca Plc - Key offerings • 62: AstraZeneca Plc - Key customers • 63: AstraZeneca Plc - Segment focus • 64: Bayer AG - Overview • 65: Bayer AG - Business segments • 66: Bayer AG - Key offerings • 67: Bayer AG - Key customers • 68: Bayer AG - Segment focus • 69: Bristol-Myers Squibb Co. - Overview • 70: Bristol-Myers Squibb Co. - Product and service • 71: Bristol-Myers Squibb Co. - Key offerings • 72: Bristol-Myers Squibb Co. - Key customers • 73: Bristol-Myers Squibb Co. - Segment focus • 74: Eli Lilly and Co. - Overview • 75: Eli Lilly and Co. - Business segments • 76: Eli Lilly and Co. - Key offerings • 77: Eli Lilly and Co. - Key customers • 78: Eli Lilly and Co. - Segment focus • 79: F. Hoffmann-La Roche Ltd. - Overview • 80: F. Hoffmann-La Roche Ltd. - Business segments • 81: F. Hoffmann-La Roche Ltd. - Key offerings • 82: F. Hoffmann-La Roche Ltd. - Key customers • 83: F. Hoffmann-La Roche Ltd. - Segment focus • 84: Gilead Sciences Inc. - Overview • 85: Gilead Sciences Inc. - Product and service • 86: Gilead Sciences Inc. - Key offerings • 87: Gilead Sciences Inc. - Key customers • 88: Gilead Sciences Inc. - Segment focus • 89: Johnson & Johnson - Overview • 90: Johnson & Johnson - Business segments • 91: Johnson & Johnson - Key offerings • 92: Johnson & Johnson - Key customers • 93: Johnson & Johnson - Segment focus • 94: Pfizer Inc. - Overview • 95: Pfizer Inc. - Business segments • 96: Pfizer Inc. - Key offerings • 97: Pfizer Inc. - Key customers • 98: Pfizer Inc. - Segment focus • 99: Currency conversion rates for US$ • 100: Research Methodology • 101: Validation techniques employed for market sizing • 102: Information sources • 103: List of abbreviations

AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Johnson & Johnson, Pfizer Inc.